Mary Ann Allison

1.3k total citations
16 papers, 540 citations indexed

About

Mary Ann Allison is a scholar working on Oncology, Cancer Research and Hematology. According to data from OpenAlex, Mary Ann Allison has authored 16 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Cancer Research and 2 papers in Hematology. Recurrent topics in Mary Ann Allison's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (3 papers). Mary Ann Allison is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (5 papers) and Breast Cancer Treatment Studies (3 papers). Mary Ann Allison collaborates with scholars based in United States, Sweden and Italy. Mary Ann Allison's co-authors include John A. Glaspy, Robert M. Elashoff, Helena R. Chang, Jeffrey Gornbein, Henri Roché, Fang Fang, Mario Campone, Dale E. Shuster, Thomas Bachelot and J. Wanders and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Mary Ann Allison

11 papers receiving 510 citations

Peers

Countries citing papers authored by Mary Ann Allison

Since Specialization

Citations

This map shows the geographic impact of Mary Ann Allison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Ann Allison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Ann Allison more than expected).

Fields of papers citing papers by Mary Ann Allison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Ann Allison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Ann Allison. The network helps show where Mary Ann Allison may publish in the future.

Co-authorship network of co-authors of Mary Ann Allison

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Ann Allison. A scholar is included among the top collaborators of Mary Ann Allison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Ann Allison. Mary Ann Allison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer 2017 ·Clinical Breast Cancer ·Cynthia Osborne, (unknown), Charles F. Eisenbeis, Frankie A. Holmes, Marcus A. Neubauer, (unknown), (unknown), S. Vukelja, Sharon Wilks, Mary Ann Allison, (unknown), Scot Sedlacek, Yunfei Wang, Lina Asmar, Joyce O’Shaughnessy	7
2	Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study 2013 ·The Lancet Oncology ·(unknown), (unknown), Devchand Paul, Scot Sedlacek, Anne Favret, Ira Gore, Deborah Lindquist, Frankie A. Holmes, Mary Ann Allison, (unknown), (unknown), Svetislava J. Vukelja, Michael S. Steinberg, Christopher Stokoe, (unknown), Yunfei Wang, Lina Asmar, Nicholas J. Robert, Joyce O’Shaughnessy	92
3	Don't Do It 2013 ·Mary Ann Allison	1
4	Differential response of triple‐negative breast cancer to a docetaxel and carboplatin‐based neoadjuvant treatment 2010 ·Cancer ·Helena R. Chang, John A. Glaspy, Mary Ann Allison, (unknown), Robert M. Elashoff, (unknown), Jeffrey Gornbein	83
5	Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS) 2010 ·Blood ·Azra Raza, Naomi Galili, Scott E. Smith, John E. Godwin, Ralph V. Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark U. Rarick, Mary Ann Allison, O.O. Melnyk, Lisa Meng, Marsha Jones, Gail L. Brown, (unknown), Mikkael A. Sekeres	2
6	Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine 2010 ·Journal of Clinical Oncology ·Javier Cortés, Linda T. Vahdat, Joanne L. Blum, Chris Twelves, Mario Campone, Henri Roché, Thomas Bachelot, Ahmad Awada, Robert Paridaens, Anthony Gonçalvès, Dale E. Shuster, J. Wanders, Fang Fang, (unknown), (unknown), Patricia E. Cole, Simon Ashworth, Mary Ann Allison	164
7	Roundtable Discussion Examining Ritual, Technology, and Community in Urban Communication 2010 ·HELIN Digital Commons ·(unknown), Mary Ann Allison, (unknown), Gary Gumpert	0
8	Phase I Study of PD 0332991, a Novel, Oral, Cyclin-D Kinase (CDK) 4/6 Inhibitor in Combination with Letrozole, for First-Line Treatment of Metastatic Post-Menopausal, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. 2009 ·Cancer Research ·RS Finn, SA Hurvitz, Mary Ann Allison, Steven Applebaum, John A. Glaspy, (unknown), Ronan Courtney, M. Naveed Shaik, (unknown), Camilla Fowst, DJ Slamon	13
9	Measuring Urban Communication 2008 ·International Communication Gazette ·Mary Ann Allison	0
10	Competing in the cauldron of the global economy: tools, processes, case studies, and theory supporting economic development 2006 ·International Journal of Technology Management ·Mary Ann Allison, (unknown)	7
11	Imagine the Loneliness of an Old Woman 2005 ·Explorations in Media Ecology ·Mary Ann Allison	1
12	The Complexity Advantage: How the Science of Complexity Can Help Your Business Achieve Peak Performance 1999 ·Medical Entomology and Zoology ·(unknown), Mary Ann Allison	77
13	Using Culture and Communications Theory in Postmodern Urban Planning 1995 ·Communication Research ·(unknown), Mary Ann Allison	4
14	Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. 1991 ·Journal of Clinical Oncology ·(unknown), Robert Mennel, (unknown), (unknown), Mary Ann Allison, (unknown), (unknown), Bryan Rea	32
15	Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. 1989 ·Journal of Clinical Oncology ·Mary Ann Allison, (unknown), (unknown)	57
16	Managing Up, Managing Down 1986 ·Medical Entomology and Zoology ·Mary Ann Allison, (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact